Skip to Content

R/R Large B-cell Lymphoma: Interesting results from ASH 2022 for treatment with Yescarta (axicabtagene ciloleucel)

Frederick L. Locke, Moffitt Cancer Center, Tampa, Florida, presents in this MEDtalk, the importance of shortening vein-to-vein time in patients treated with axicabtagene ciloleucel (real-world data) and the association of metabolic tumor volume and clinical outcome after second-line treatment with axicabtagene ciloleucel versus standard of care.

Frederick Locke

Få tilgang til artikkelen

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top